Niraparib improves PFS in Chinese patients with ovarian cancer
15 Dec 2020
byElaine Soliven
An individualized dosing regimen of niraparib, a potent inhibitor of PARP 1/2, resulted in significantly improved progression-free survival (PFS) among Chinese patients with platinum-sensitive recurrent (PSR) ovarian cancer, according to a subgroup analysis of the NORA* study presented at ESMO Asia 2020.